Business / Finance

RSS

Trinean, Sony DADC sign manufacturing and supply agreement to develop microfluidic disposables

Trinean, the leading provider of microfluidic spectrophotometry platforms, today announced that it entered into a manufacturing and supply agreement with Sony DADC for the production of microfluidic disposables fit for storage and micro-cuvette analysis of droplet-sized biological samples.

1 Apr 2014

PPG sells its ownership interest in transitions optical joint venture to Essilor International

PPG Industries, Inc. today announced the successful completion of the previously announced sale to Essilor International of its 51 percent ownership interest in its Transitions Optical joint venture and PPG's wholly-owned sunlens business.

1 Apr 2014

GIN and Sigolis merge to create new company, Ginolis Oy

Global Innovation Network Oy (GIN) and Sigolis AB today announced a merger of the two companies. The new company, named Ginolis Oy, provides an innovative one-stop solution for the development and manufacturing of in vitro diagnostic (IVD) disposable products.

1 Apr 2014

Teva granted certiorari petition related to Mylan's ANDA for Copaxone

Mylan Inc. announced that today the Supreme Court of the United States granted certiorari in Mylan's patent litigation against Teva relating to Mylan's Abbreviated New Drug Application (ANDA) for glatiramer acetate (Copaxone).

1 Apr 2014

Antibe Therapeutics closes previously announced non-brokered private placement

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") has closed its previously announced non-brokered private placement raising gross proceeds of $3,015,398 (the "Offering") on the sale of 5,025,664 Common Shares of the Corporation.

1 Apr 2014

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Pacira Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL (bupivacaine liposome injectable suspension). The suite is housed at the company's Science Center Campus in San Diego, where EXPAREL is currently manufactured.

31 Mar 2014

Verde Media Group, Biotech Division complete acquisition of Butazyme

Verde Media Group Inc. and its Biotech Division announce they have completed the acquisition of the privately held biotechnology company Butazyme LLC.

31 Mar 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

FitLife Brands' fourth quarter 2013 revenue increases 9% to $3.7 million

FitLife Brands, Inc., an international provider of innovative and proprietary nutritional supplements for health conscious consumers marketed under the brand names NDS Nutrition Products, PMD, SirenLabs and CoreActive today announced financial results for the fiscal year ended December 31, 2013.

31 Mar 2014

ICON agrees to acquire Aptiv Solutions for $143.5 million

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to certain closing conditions, to acquire Aptiv Solutions for a cash consideration of $143.5 million. Aptiv Solutions is owned by The Halifax Group, SV Life Sciences, Comvest Partners and Management.

31 Mar 2014

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727.

31 Mar 2014

Dongkook Pharmaceutical to launch Probi Mage dietary supplement in South Korea

Probi has signed a distribution agreement with Dongkook Pharmaceutical Co., Ltd., based in Seoul, South Korea for the distribution of Probi´s gut health product, Probi Mage®. The Product will be launched under Probi's brand in South Korea in the second quarter of 2014.

31 Mar 2014

Panasonic and KKR complete share purchase agreement

Panasonic Corporation ("Panasonic") and KKR, a leading global investment firm, today announced the completion of a share purchase agreement and a shareholders' agreement under which Panasonic and KKR have become joint partners of Panasonic Healthcare Co., Ltd. ("Panasonic Healthcare").

From PHC Europe B.V. 31 Mar 2014

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group plc ('Clinigen' or the 'Group') the specialty global pharmaceutical company today announces the acquisition of SAVENE® (dexrazoxane) from SpePharm AG, a majority owned affiliate of Norgine B.V. The Financial terms of the acquisition are not being disclosed.

From Clinigen Group 31 Mar 2014

Otsuka acquires rights to develop and sell Eisai’s DACOGEN in the US, Canada and Japan

Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license for DACOGEN® (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd., giving Otsuka full development and commercialization rights for the product in the former Eisai territories of the United States, Canada and Japan.

31 Mar 2014

Aeterna Zentaris declares effectiveness of Form F-3 shelf registration statement filed with SEC

Aeterna Zentaris Inc. (the "Company") today announced that its shelf registration statement on Form F-3 previously filed with the Securities and Exchange Commission (the "SEC") has been declared effective by the SEC.

29 Mar 2014

RXi Pharmaceuticals provides business update, reports Q4 and full year 2013 financial results

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.

29 Mar 2014

Nephros’ total revenues decrease $67,000 to 4% in the year ended December 31, 2012

Nephros, Inc., a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today financial results for the three months and full year ended December 31, 2013.

29 Mar 2014

Nautilus offers second-look financing to Genesis Credit

Nautilus, Inc., a leader in innovative home fitness equipment, is pleased to announce a partnership with Genesis Financial Solutions to offer Genesis Credit second-look financing.

29 Mar 2014

Antibe Therapeutics increases previously announced non-brokered private placement to up to $5,000,000

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce, based on increased inbound demand, that the previously announced non-brokered private placement (the "Offering") has been increased to up to $5,000,000 on the same terms and conditions as announced in Antibe's press release dated March 21, 2014.

29 Mar 2014

Business / Finance

Trinean, Sony DADC sign manufacturing and supply agreement to develop microfluidic disposables

PPG sells its ownership interest in transitions optical joint venture to Essilor International

GIN and Sigolis merge to create new company, Ginolis Oy

Teva granted certiorari petition related to Mylan's ANDA for Copaxone

Antibe Therapeutics closes previously announced non-brokered private placement

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Verde Media Group, Biotech Division complete acquisition of Butazyme

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

FitLife Brands' fourth quarter 2013 revenue increases 9% to $3.7 million

ICON agrees to acquire Aptiv Solutions for $143.5 million

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Dongkook Pharmaceutical to launch Probi Mage dietary supplement in South Korea

Panasonic and KKR complete share purchase agreement

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Otsuka acquires rights to develop and sell Eisai’s DACOGEN in the US, Canada and Japan

Aeterna Zentaris declares effectiveness of Form F-3 shelf registration statement filed with SEC

RXi Pharmaceuticals provides business update, reports Q4 and full year 2013 financial results

Nephros’ total revenues decrease $67,000 to 4% in the year ended December 31, 2012

Nautilus offers second-look financing to Genesis Credit

Antibe Therapeutics increases previously announced non-brokered private placement to up to $5,000,000

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News